D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity - PubMed

D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity

Dhanasekharan Muralikrishnan et al. Synapse. 2003 Oct.

Abstract

Selegiline (L-deprenyl) is believed to render protection against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity to a significant extent via a free radical scavenging mechanism, which is independent of its ability to inhibit monoamine oxidase-B (MAO-B) in the brain. We investigated the hydroxyl radical (.OH) scavenging action and neuroprotective effect of D-deprenyl, its less active isomer, in MPTP-induced dopaminergic neurotoxicity in mice to test whether the chemical structure of the molecule or its biological effects contribute to this property. To achieve this goal we studied the effects of D-deprenyl on: (1).OH production in a Fenton reaction; (2) MPTP-induced.OH generation and dopamine (DA) depletion in vivo, employing a sensitive HPLC-electrochemical procedure; and (3) formation of MPP(+) in vivo in the striatum following systemic administration of MPTP, employing an HPLC-photodiode array detection system. D-deprenyl inhibited ferrous citrate-induced.OH in vitro (0.45 microM) and MPTP-induced.OH in vivo in substantia nigra (SN) and in the striatum (1.0 mg/kg, i.p.). D-deprenyl did not, but L-deprenyl (0.5 mg/kg dose) did significantly inhibit formation of MPP(+) in the striatum 90 min following systemic MPTP injection. It failed to affect MAO-B activity at 0.5 mg/kg in the striatum, but effectively blocked MPTP-induced striatal DA depletion. The potency of D-deprenyl to scavenge MPTP-induced.OH in vivo and to render protection against the dopaminergic neurotoxicity without affecting dopamine turnover, MAO-B activity, or formation of MPP(+) in the brain indicates a direct involvement of.OH in the neurotoxic action of MPTP and antioxidant effect in the neuroprotective action of deprenyl.

Similar articles

• Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.

  Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH. Kupsch A, et al. J Neural Transm (Vienna). 2001;108(8-9):985-1009. doi: 10.1007/s007020170018. J Neural Transm (Vienna). 2001. PMID: 11716151

• Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.

  Knaryan VH, Samantaray S, Varghese M, Srinivasan A, Galoyan AA, Mohanakumar KP. Knaryan VH, et al. Neuropeptides. 2006 Aug;40(4):291-8. doi: 10.1016/j.npep.2006.03.005. Epub 2006 May 18. Neuropeptides. 2006. PMID: 16712929

• Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.

  Wu WR, Zhu XZ, Guan HJ, Wang RG, Ji XQ. Wu WR, et al. Zhongguo Yao Li Xue Bao. 1999 Feb;20(2):146-50. Zhongguo Yao Li Xue Bao. 1999. PMID: 10437162

• Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).

  Wu RM, Mohanakumar KP, Murphy DL, Chiueh CC. Wu RM, et al. Ann N Y Acad Sci. 1994 Nov 17;738:214-21. doi: 10.1111/j.1749-6632.1994.tb21806.x. Ann N Y Acad Sci. 1994. PMID: 7832430 Review.

• The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.

  Jenner P, Marsden CD. Jenner P, et al. J Neural Transm Suppl. 1986;20:11-39. J Neural Transm Suppl. 1986. PMID: 3091760 Review.

Cited by

• The Neuroprotective Effects of Thymoquinone: A Review.

  Farkhondeh T, Samarghandian S, Shahri AMP, Samini F. Farkhondeh T, et al. Dose Response. 2018 Apr 11;16(2):1559325818761455. doi: 10.1177/1559325818761455. eCollection 2018 Apr-Jun. Dose Response. 2018. PMID: 29662431 Free PMC article.

• Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.

  Wahdan SA, Tadros MG, Khalifa AE. Wahdan SA, et al. Naunyn Schmiedebergs Arch Pharmacol. 2017 Sep;390(9):905-917. doi: 10.1007/s00210-017-1392-1. Epub 2017 Jun 23. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28643087 Retracted.

• Selegiline Improves Cognitive Impairment in the Rat Model of Alzheimer's Disease.

  Basir HS, Mirazi N, Komaki A, Mohamadpour B, Hosseini A. Basir HS, et al. Mol Neurobiol. 2025 Feb;62(2):2548-2560. doi: 10.1007/s12035-024-04388-x. Epub 2024 Aug 13. Mol Neurobiol. 2025. PMID: 39136906

• Disease modification in Parkinson's disease.

  Henchcliffe C, Severt WL. Henchcliffe C, et al. Drugs Aging. 2011 Aug 1;28(8):605-15. doi: 10.2165/11591320-000000000-00000. Drugs Aging. 2011. PMID: 21812497 Review.

• Protective effects of selegiline against amyloid beta-induced anxiety-like behavior and memory impairment.

  Mohamadpour B, Mirazi N, Komaki A, Basir HS, Hosseini A. Mohamadpour B, et al. Brain Behav. 2024 Jun;14(6):e3599. doi: 10.1002/brb3.3599. Brain Behav. 2024. PMID: 38873869 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley